Search

6 result(s) for 'author#Dennis Kannenkeril' within BMC

1. Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study

   After initiating cardioprotective agents, a fall of estimated glomerular filtration rate (eGFR) has been reported in several studies. Our goal was to evaluate the accuracy of change of Chronic Kidney Disease E...

   Authors: Julie Kolwelter, Kristina Striepe, Agnes Bosch, Dennis Kannenkeril, Christian Ott, Mario Schiffer and Roland E. Schmieder

   Citation: Diabetology & Metabolic Syndrome 2022 14:102

   Content type: Research Published on: 21 July 2022

   • View Full Text
   • View PDF

2. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

   In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on l-arginine (Arg) related risk mar...

   Authors: Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F. Fromm, Roland E. Schmieder and Renke Maas

   Citation: Cardiovascular Diabetology 2022 21:4

   Content type: Original investigation Published on: 6 January 2022

   • View Full Text
   • View PDF

3. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

   Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

   Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2021 20:178

   Content type: Original investigation Published on: 4 September 2021

   • View Full Text
   • View PDF

4. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

   Empagliflozin has been shown to reduce cardiovascular mortality, but the underlying pathogenetic mechanisms are poorly understood. It was previously demonstrated that empagliflozin improved arterial stiffness.

   Authors: Agnes Bosch, Christian Ott, Susanne Jung, Kristina Striepe, Marina V. Karg, Dennis Kannenkeril, Thomas Dienemann and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2019 18:44

   Content type: Original investigation Published on: 29 March 2019

   • View Full Text
   • View PDF

5. Early vascular parameters in the micro- and macrocirculation in type 2 diabetes

   Diabetes converts from a metabolic disorder into a predominantly vascular disease, once its duration extends over several years or/and when additional cardiovascular risk factors such as hypertension coexist. ...

   Authors: Dennis Kannenkeril, Agnes Bosch, Joanna Harazny, Marina Karg, Susanne Jung, Christian Ott and Roland E. Schmieder

   Citation: Cardiovascular Diabetology 2018 17:128

   Content type: Original investigation Published on: 19 September 2018

   • View Full Text
   • View PDF

6. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

   Sodium tissue content by ²³Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular c...

   Authors: M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder and R. E. Schmieder

   Citation: Cardiovascular Diabetology 2018 17:5

   Content type: Original investigation Published on: 4 January 2018

   • View Full Text
   • View PDF